WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573273

CAS#: 119-96-0

Description: Arsthinol is an antiprotozoal agent which may have anti-cancer activity. It was found that arsthinol, a trivalent organoarsenic compound (dithiarsolane), has been active in vitro on leukemia cell lines and offers a better therapeutic index than arsenic trioxide, as estimated by the ratio LD50/IC50. Arsthinol induced growth inhibition of NB4 cells at lower concentration (IC50 (concentration inhibiting growth by 50%) = 0.78 +/- 0.08 micromol/l after 24 h) than As(2)O(3) (IC50 = 1.60 +/- 0.23 micromol/l after 24 h) or melarsoprol (IC50 = 1.44 +/- 0.08 micromol/l after 24 h). Arsthinol-cyclodextrin complex demonstrated to have was more effective than arsenic trioxide (As2O3) and melarsoprol on the U87 MG cell line. Importantly, in the in vivo study, significant antitumor activity against heterotopic xenografts was observed after i.p. administration.

Chemical Structure

CAS# 119-96-0

Theoretical Analysis

MedKoo Cat#: 573273
Name: Arsthinol
CAS#: 119-96-0
Chemical Formula: C11H14AsNO3S2
Exact Mass: 346.9631
Molecular Weight: 347.28
Elemental Analysis: C, 38.04; H, 4.06; As, 21.57; N, 4.03; O, 13.82; S, 18.46

Price and Availability

Size Price Availability Quantity
1.0mg USD 85.0 Ready to ship
5.0mg USD 150.0 Ready to ship
10.0mg USD 250.0 Ready to ship
25.0mg USD 550.0 Ready to ship
50.0mg USD 950.0 Ready to ship
100.0mg USD 1650.0 Ready to ship
200.0mg USD 2950.0 Ready to ship
Bulk inquiry

Synonym: Arsthinenol; Arsthinol; Balarsen; Mercaptoarsenol;

IUPAC/Chemical Name: N-(2-hydroxy-5-(4-(hydroxymethyl)-1,3,2-dithiarsolan-2-yl)phenyl)acetamide


InChi Code: InChI=1S/C11H14AsNO3S2/c1-7(15)13-10-4-8(2-3-11(10)16)12-17-6-9(5-14)18-12/h2-4,9,14,16H,5-6H2,1H3,(H,13,15)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 347.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Becherirat S, Lanhers MC, Socha M, Yemloul M, Astier A, Loboda C, Aniceto N, Gibaud S. The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):560-8. doi: 10.1016/j.ejpb.2013.06.021. Epub 2013 Jul 4. PMID: 23831266.

2: Ajana I, Astier A, Gibaud S. Speciation of arsenic in urine following intravenous administration of arsthinol in mice. Eur J Drug Metab Pharmacokinet. 2010 Sep;35(1-2):59-65. doi: 10.1007/s13318-010-0009-6. PMID: 21495268.

3: Ajana I, Astier A, Gibaud S. Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. J Pharm Pharmacol. 2009 Oct;61(10):1295-301. doi: 10.1211/jpp/61.10.0004. PMID: 19814860.

4: Gibaud S, Astier A. Organoarséniés dérivés du 2-phényl- [1,3,2]dithiarsolane-4-yl)-méthanol (AsIII) à propriétés antileucémiques: des trypanosomicides aux anticancéreux [Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs]. Ann Pharm Fr. 2007 May;65(3):162-8. French. doi: 10.1016/s0003-4509(07)90031-0. PMID: 17489071.

5: Hiskey CF, Cantwell FF. Ultraviolet spectrum correlations with the conjugate acid-base species of acetarsone and arsthinol. J Pharm Sci. 1968 Dec;57(12):2105-11. doi: 10.1002/jps.2600571217. PMID: 5708352.

6: GOLDMAN L, PRESTON RH, MEISTER M. Arsthinol (Balarsen) in dermatology. Dermatologica. 1956 Dec;113(6):369-74. doi: 10.1159/000256212. PMID: 13414432.

7: BROWN CH, GEBHART WF, REICH A. Intestinal amebiasis; incidence, symptoms, and treatment with arsthinol (balarsen). J Am Med Assoc. 1956 Feb 4;160(5):360-3. doi: 10.1001/jama.1956.02960400018005. PMID: 13278204.

8: KUHN BH. Balarsen: a new oral arsenical in the treatment of pustular bacterid; case report. W V Med J. 1956 Feb;52(2):48-9. PMID: 13291781.

9: RAVINA A. Une nouvelle médication de l'amibiase, le mercaptoarsenical [A new amebiasis medication, the mercapto-arsenical]. Presse Med. 1956 Jan 7;64(2):29-30. French. PMID: 13289703.

10: LOUGHLIN EH, JOSEPH AA, MULLIN WG. The treatment of amebiasis with arsthinol (N.N.R) (balarsen). Antibiot Chemother (Northfield). 1954 Jun;4(6):647-8. PMID: 24543096.

11: MOST H, VAN ASSENDELFT F, MILLER J, MILBERG MB, ROSSMAN EB. Arsthinol (balarsen), a new trivalent arsenical for the treatment of intestinal amebiasis and other intestinal protozoa. Am J Trop Med Hyg. 1954 Mar;3(2):262-5. PMID: 13138828.

12: NEW and nonofficial remedies; arsthinol. J Am Med Assoc. 1953 Jun 6;152(6):531. PMID: 13044569.

13: LINDNER E. Obrat na hlavi6cku p6ri poloze podélné koncem pánevnäm [Rotation of the head in pelvic presentation]. Cesk Gynekol. 1953 Jun;18(3):222-31. Undetermined Language. PMID: 13082581.